Stephens Inc. AR Has $15.50 Million Stock Holdings in Abbott Laboratories $ABT

Key Points

• Stephens Inc. AR reduced its holdings in Abbott Laboratories by 11.5% during the second quarter, now owning 113,988 shares valued at approximately $15.50 million.
• The company recently declared a quarterly dividend of $0.59 per share, representing an annualized yield of 1.8% for shareholders of record.
• Analysts have set new price targets for Abbott Laboratories, with Barclays increasing their target to $162.00 and several others suggesting a strong buy rating.

Stephens Inc. AR decreased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 11.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 113,988 shares of the healthcare product maker's stock after selling 14,856 shares during the period. Stephens Inc. AR's holdings in Abbott Laboratories were worth $15,504,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Avanza Fonder AB boosted its position in Abbott Laboratories by 0.4% in the second quarter. Avanza Fonder AB now owns 168,401 shares of the healthcare product maker's stock valued at $22,904,000 after buying an additional 655 shares in the last quarter. Madrona Financial Services LLC boosted its position in Abbott Laboratories by 9.7% in the second quarter. Madrona Financial Services LLC now owns 1,726 shares of the healthcare product maker's stock valued at $235,000 after buying an additional 152 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Abbott Laboratories by 12.4% in the second quarter. Janney Montgomery Scott LLC now owns 669,868 shares of the healthcare product maker's stock valued at $91,109,000 after buying an additional 73,780 shares in the last quarter. SageView Advisory Group LLC boosted its position in Abbott Laboratories by 18.6% in the first quarter. SageView Advisory Group LLC now owns 18,294 shares of the healthcare product maker's stock valued at $2,427,000 after buying an additional 2,873 shares in the last quarter. Finally, Cerity Partners LLC lifted its holdings in shares of Abbott Laboratories by 49.8% during the first quarter. Cerity Partners LLC now owns 1,507,268 shares of the healthcare product maker's stock worth $199,939,000 after purchasing an additional 501,200 shares during the period. Institutional investors and hedge funds own 75.18% of the company's stock.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $128.69 on Monday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The firm has a fifty day simple moving average of $132.38 and a 200 day simple moving average of $131.54. The company has a market capitalization of $223.98 billion, a PE ratio of 16.13, a P/E/G ratio of 2.44 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts' consensus estimates of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The business had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter last year, the firm earned $1.21 earnings per share. Abbott Laboratories's quarterly revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's payout ratio is 29.57%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Barclays lifted their price target on shares of Abbott Laboratories from $159.00 to $162.00 and gave the stock an "overweight" rating in a report on Friday. Benchmark assumed coverage on shares of Abbott Laboratories in a report on Friday, October 10th. They set a "buy" rating and a $145.00 price target on the stock. Weiss Ratings reiterated a "buy (b)" rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. Raymond James Financial lifted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, The Goldman Sachs Group lifted their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a "buy" rating in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $147.61.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.